A therosclerosis is a major cause of morbidity and mortality in western countries. Atherosclerotic lesions within major blood vessels are responsible for myocardial infarction, strokes, and peripheral vascular disease. The initial event in the development of the atherosclerotic lesion is the adhesion of monocytes to the endothelial cells of the blood vessel wall and the extravasation of monocytes into the subendothelial space. 1, 2 Recruited monocytes differentiate into macrophages and accumulate modified forms of LDL via scavenger receptors to yield lipid-laden foam cells. 3 Chronic recruitment of mononuclear cells into the developing lesion contributes to the growth of lesions and occlusion of the blood vessel. 4 Macrophages and T cells within atherosclerotic lesions produce an array of cytokines, growth factors, and inflammatory mediators, which are likely to play a role in continued mononuclear cell recruitment. 5, 6 Chemoattractant cytokines (chemokines) are small disulfide-linked polypeptides of typically 60 to 70 amino acids in length that are potent chemoattractants for leukocytes. 7 The chemokine supergene family, which was unrecognized 10 years ago, now has Ͼ40 different members classified into different subfamilies on the basis of conserved structural features. 8, 9 The CXC (or ␣) chemokines have a single amino acid separating the first 2 cysteine residues of the protein, whereas CC (or ␤) chemokines have no amino acid separating the signature C1 and C2 cysteines. The CC chemokine monocyte chemotactic protein-1 (MCP-1/CCL2), a potent chemoattractant for monocytes, has been shown to be expressed in human atherosclerotic lesions. 10, 11 Mice homozygous for a targeted deletion of the MCP-1 gene or the gene that encodes the MCP-1 receptor CCR2 exhibit a reduced incidence of atherosclerotic lesions when they are fed a high-fat diet. 12, 13 The involvement of chemokines other than MCP-1 in the pathogenesis of atherosclerosis is suggested by the observation that lethally irradiated LDL receptorknockout mice repopulated with bone marrow from CXCR2-deficient mice had smaller aortic lesions with reduced numbers of recruited monocytes. 14 Fractalkine/CX 3 CL1 is a novel chemokine that differs from other chemokines in that it has 3 intervening amino acids between the 2 cysteine residues of the chemokine motif (CX 3 C) and exists as a membrane-bound molecule with the chemokine motif attached to a long mucin stalk. 15 When cleaved from the cell surface, soluble forms of fractalkine mediate the chemotaxis of monocytes and T cells. 15 Immobilized forms of fractalkine have been shown to mediate tight adhesion of cells carrying the CX 3 CR1 receptor, and this adhesion does not require integrins, calcium, or an opposing cell membrane. 16 Furthermore, fractalkine-dependent firm adhesion of monocytes and T cells can occur under flow conditions. 17 We have analyzed the expression of macrophage-derived chemokine (MDC), fractalkine, and thymus-and activationregulated chemokine (TARC), which are linked chromosome 16q13 chemokines, in primary human macrophages and in atherosclerotic lesions of human arteries. Macrophage expression of MDC and TARC is upregulated by the Th2 cytokines interleukin (IL)-4 and IL-13 but not by IL-10 or the Th1 cytokine interferon-␥ (IFN-␥). The chemokines MDC, fractalkine, and TARC are expressed by a subset of macrophages within human atherosclerotic plaques associated with intraplaque microvessels in regions of neovascularization.
Methods

Human Tissues
Aortic tissue samples used for RNA preparations were obtained from transplant organ donors (10 females and 10 males, aged 16 to 66 years), and carotid tissue samples were obtained from patients undergoing endarterectomy (2 females and 8 males, aged 66 to 82 years). The use of discarded human tissue for research purposes was approved by the Ethics Committee of Addenbrooke's Hospital, Cambridge. The arterial samples used for immunohistochemistry were obtained from patients undergoing surgical procedures at the John Radcliffe Hospital, Oxford. The use of discarded human tissue for research purposes was approved by the Central Oxford Research Ethics Committee.
Human Primary Cell Culture
Macrophages were prepared from peripheral blood mononuclear cells (PBMCs) by adhesion. Briefly, PBMCs prepared from buffy coats by Ficoll centrifugation were incubated in a 225-cm 2 tissue culture flask for 3 hours and washed once with PBS to eliminate unattached cells. After 3 days in culture, serum-free medium (X-Vivo-10, Bio-Whittaker) containing IFN-␥, IL-4, IL-10, or IL-13 (69 ng/mL, R&D Systems) was added, and this was repeated on alternate days. Cells were harvested after 72 hours with the use of 1 mmol/L EDTA. Immature dendritic cells (DCs) were prepared by using a similar protocol, except that PBMCs were depleted of CD2 ϩ cells by using Dynal beads before adhesion to tissue culture plastic; IL-4 and granulocyte-macrophage colony-stimulating factor (66 ng/mL) were added every other day for 7 days. Mature DCs were prepared by transferring immature DCs to macrophage-conditioned medium supplemented with IL-4 and granulocyte-macrophage colony-stimulating factor on day 7, and RNA was prepared on day 9.
Western Blotting
Supernatant medium was harvested from macrophage cultures and fractionated by electrophoresis on 15% polyacrylamide/SDS gels before transfer to Hybond-C nylon membranes (Amersham). Blocked filters were incubated with a goat anti-human TARC antiserum (R&D Systems) or a rabbit anti human MDC antiserum (Peprotec). Filters were incubated with appropriate secondary antibodies (Jackson Laboratories) and visualized by enhanced chemiluminescence (ECL kit, Amersham).
RNA Preparation and RT-PCR
Arterial tissue samples were dispersed by collagenase and elastase digestion, and cells were lysed in 150 mmol/L NaCl, 10 mmol/L Tris-HCl (pH 7.4), 1 mmol/L MgCl 2 , and 0.5% Nonidet P-40. Nuclei were pelleted by centrifugation, and the supernatant was adjusted to 1.5% SDS, extracted twice with Tris-buffered phenol, and ethanolprecipitated. Precipitated RNA was digested with RNase-free DNase I (Promega). Total RNA (5 g) was used as a template in a 60-minute reverse transcription (RT) reaction at 42°C by using oligo dT [12] [13] [14] [15] [16] [17] [18] primer and avian myeloblastosis virus reverse transcriptase. The resultant cDNA preparations were used as templates in 20 L RT-polymerase chain reaction (PCR) reactions containing 10 mmol/L Tris-HCl (pH 9.0), 50 mmol/L KCl, 1.5 mmol/L MgCl 2 , 0.1% Triton X-100, 0.2 mmol/L each dNTP, 250 ng each primer, and 2.5 U Taq Polymerase (Promega). The following primers were used for RT-PCR reactions: fractalkine, 5Ј ATGACATCAAAGATAC-CTGTAGC and 5Ј AGGCAATCGGAAAAGGTCC; MDC, 5Ј ACAGACTGCACTCCTGGTTG and 5Ј GCTCAGCTTATT-GAGAATCATC; TARC, 5Ј GGACCTGCACACAGAGAG-AGAGACTC and 5Ј GGTACCACGTCTTCAGCTTTC; CD68, 5Ј GAGGCCTGGGGCATCTCTGTA and 5Ј CGAGTTGCTG-CAACTGAAGCT; and ␤ 2 -microglobulin, 5Ј GATTCAGGTT-TACTCACG and 5Ј CCATGATGCTGCTTACATG. RT-PCR reactions were performed for 30 amplification cycles (94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 90 seconds), except for ␤ 2 -microglobulin and CD68 reactions, which were amplified for 25 cycles. Half of each RT-PCR reaction was run on a 1% agarose gel and transferred to Hybond NX nylon membranes (Amersham) by Southern blotting. Filters were hybridized with [␣-
32 P]dCTP-labeled probe fragments, and the amount of amplified product in each sample was measured by using electronic autoradiography (Instant Imager, Packard). Serial dilutions of cDNA samples were analyzed to show that the RT-PCR signal was directly proportional to the amount of cDNA template.
Immunohistochemistry
The preparation of an anti-fractalkine-specific antiserum with use of a synthetic peptide corresponding to amino acids 352 to 370 of the intracellular domain of the fractalkine has been described previously. 18 An affinity-purified anti-amino terminal fractalkine rabbit antiserum 15 was a gift of Dr Thomas Schall (ChemoCentryx Inc, San Carlos, Calif.). Serial paraffin-embedded sections (7 to 10 m) and frozen sections (7 m) embedded in OCT (Miles Laboratories) were incubated with the following antibodies: mouse monoclonal antibody (mAb) against human CD68 (1:300 dilution, KP-1, Dako), mouse mAb against muscle ␣-and ␥-actin (1:50 dilution, HHF35, Enzo Diagnostics), and mouse mAb against human von Willebrand factor (1:600 dilution, F8/86, Dako). Human MDC expression was detected by using IgG purified from the serum of a rabbit immunized with recombinant human MDC (Peprotec), and human TARC was detected by using an affinity-purified goat anti-human TARC antiserum (R&D Systems). Affinity-purified polyclonal antisera raised against synthetic fractalkine peptides were used at a concentration of 100 ng/mL. The TM-Plus avidin-biotin-horseradish peroxidase detection system (Zymed Laboratories) was used for detection of bound antibodies; diaminobenzidine was used as a color substrate. Sections were counterstained with hematoxylin. Irrelevant class-and species-matched immunoglobulins were used as controls.
Results
Localization of the MDC, Fractalkine, and TARC Genes to Chromosome 16q13
We have reported previously that the human fractalkine gene is mapped to chromosome 16 by analysis of somatic cell hybrids. 15 We isolated 3 cosmids and a P1 artificial chromosome (PAC) clone from chromosome 16 genomic DNA libraries with the use of fractalkine cDNA probes ( Figure 1A ). Cosmid c325D6 was labeled with biotin and hybridized to G-banded metaphase spreads in fluorescent in situ hybridization experiments that localized the fractalkine gene to chromosome 16q13 (data not shown). Analysis of the Genebridge IV radiation hybrid panel with fractalkine-specific PCR primers mapped the fractalkine gene between the framework markers D16S408 and D16S503 (data can be accessed online at http://sunny.ebi.ac.uk/RHdb/, accession No. RH86440). The MDC and TARC genes have been mapped to this same region of chromosome 16. 19 Analysis of the fractalkine gene containing cosmids and the PAC clone by use of long-distance PCR, Southern blotting, and DNA sequencing showed that the MDC, fractalkine, and TARC genes are physically linked and are in the same transcriptional orientation ( Figure 1A ).
Expression of Chromosome 16q13 Chemokines in Mononuclear Phagocytes
A cDNA clone encoding MDC was originally isolated from a macrophage cDNA library, 20 and MDC expression by macrophages has been reported to be upregulated by bacterial endotoxin 21 and treatment with Th2-type cytokines. 22 By contrast, TARC has been reported to be a DC-specific marker. 23 We prepared macrophages and DCs from PBMCs and analyzed the expression of the linked chromosome 16q13 chemokines by RT-PCR. MDC mRNA expression in primary macrophages is markedly induced by treatment with the Th2-type cytokine IL-4 ( Figure 1B) . Similar results were obtained with macrophages prepared from 4 different donors. Although the level of MDC expression in untreated macrophages varied between donors, all 4 donors showed a 5-to 10-fold increase in MDC mRNA expression on addition of IL-4. TARC mRNA is readily detectable in immature and mature DCs and is induced by IL-4 treatment of primary human macrophages ( Figure 1B) . A similar pattern of expression is seen with the use of fractalkine-specific PCR primers, but the level of expression of fractalkine mRNA is lower than that for MDC or TARC. Supernatant medium was collected from IL-4 -treated macrophages and analyzed by Western blotting. The data of Figure 1C show that secretion of TARC into the medium is completely dependent on the addition of IL-4; similar results were obtained with macrophages from 3 independent donors.
We analyzed MDC and TARC mRNA expression by human primary macrophages treated with other cytokines characteristic of Th2-and Th1-type immune responses. Figure 2 shows that macrophage expression of MDC and TARC mRNA is markedly upregulated by treatment with IL-4 and IL-13 but not by treatment with IL-10 or the Th1 cytokine IFN-␥. Cytokine-treated macrophages show similar levels of CD68 mRNA (Figure 2) , and significant differences in gene expression in IL-10 -and IFN-␥-treated macrophages were detected in differential display RT-PCR experiments (data not shown).
Fractalkine, MDC, and TARC mRNA Expression in Human Arteries
We undertook a semiquantitative RT-PCR analysis of fractalkine, MDC, and TARC expression in RNA prepared from a panel of 30 human aortic and carotid artery tissue samples, which had been selected for evidence of calcified plaques (C. Shanahan, K. Tyson, P.L. Wessberg, unpublished data, 2001). RNA samples 1 through 10 were prepared from aortic samples that contained fatty streak lesions, samples 11 through 20 were prepared from aortic samples with calcified type IV atherosclerotic plaques, and RNA samples 21 through 30 were prepared from material removed at carotid endarterectomy. Southern blots of RT-PCR reactions were performed with equal amounts of cDNA, and chemokine expression levels are shown in Figure 3 . Approximately equal amounts of ␤ 2 -microglobulin RT-PCR product were obtained with each cDNA sample. The level of fractalkine mRNA relative to a reference mRNA, ␤ 2 -microglobulin, varies Ͼ70-fold 
Fractalkine, MDC, and TARC Expression in Human Atherosclerotic Lesions
We have developed an anti-fractalkine antiserum that recognizes the intracellular domain of the transmembrane fractalkine molecule. 18 Using an antibody that specifically recognizes only the intracellular portion of fractalkine allows us to detect cells that express fractalkine in vivo. We used this antiserum and reagents that specifically detect human MDC and TARC to examine chromosome 16q13 chemokine expression in human atherosclerotic lesions. Figure 4 shows immunohistochemical analysis of serial sections of an atherosclerotic plaque in a carotid artery removed at endarterectomy. Staining with an anti-CD68 antibody shows the presence of large numbers of macrophages within the carotid plaque ( Figure 4A ). An anti-smooth muscle actin antibody shows that there are very few smooth muscle cells within the macrophage-rich region of the plaque except for those present in arterioles ( Figure 4B ). The specificity of antibody staining was demonstrated by using an isotype-matched mouse monoclonal antibody ( Figure 4C ). An affinity-purified antiserum that specifically detects MDC stains a subset of macrophages within the shoulder region of the atherosclerotic plaque stain but does not stain the endothelium of intraplaque microvessels ( Figure 4D) ; no MDC staining was seen in a normal radial arterial sample (data not shown). A very similar pattern of expression is seen with the use of an antiserum that specifically recognizes the intracellular domain of fractalkine ( Figure 4E ). An antiserum that has been reported to detect the chemokine domain of fractalkine 24 stains macrophages, smooth muscle cells, and endothelium in an adjacent section of the same lesion ( Figure 4F ). This antibody stains smooth muscle cells and endothelium in normal arterial samples (data not shown). We have shown that this anti-fractalkine reagent cross-reacts with recombinant human CD84, 18 and this most likely accounts for the different staining pattern obtained with the different anti-fractalkine reagents. A similar pattern of chemokine expression was seen in 6 independent carotid endarterectomy samples (see Table) .
We extended our immunohistochemical analysis to atherosclerotic lesions in femoral and popliteal arteries obtained after surgical procedures (see Table) . Figure I (which can be accessed online at http://atvb.ahajournals.org) shows immu- RNA from a panel of 30 human aortic and carotid arterial tissue samples that was used to prepare cDNA and chemokine gene expression was analyzed by RT-PCR. RNA samples 1 through 10 were prepared from aortic samples that contained fatty streak lesions, samples 11 through 20 were prepared from aortic samples with calcified type IV atherosclerotic plaques, and RNA samples 21 through 30 were prepared from material removed at carotid endarterectomy. Southern blots of RT-PCR reactions were performed with cDNA prepared from equal amounts of mRNA and probed with indicated cDNAs, and the levels of chemokine gene expression relative to expression of ␤2M in the same sample are shown. Serial dilutions of cDNA samples were used to confirm that the autoradiographic signal intensity was proportional to input cDNA concentration.
nohistochemical analysis of chemokine expression in an atheromatous lesion of the common femoral artery. CD68 staining shows numerous macrophages in the shoulder region of the plaque ( Figure IA and IC) , and the presence of smooth muscle cells in this area is revealed by staining with the anti-actin antibody ( Figure ID 
Discussion
We have analyzed the expression pattern of the linked chemokine genes MDC, fractalkine, and TARC in normal human arteries and in atherosclerotic lesions. All 3 chemokines are expressed in human atherosclerotic plaques by a subset of macrophages within the atherosclerotic lesion, often associated with regions of neovascularization. We have shown that MDC, fractalkine, and TARC expression by primary human macrophages is upregulated by treatment with the Th2-type cytokines IL-4 and IL-13 but not by the IL-10 or the Th1-type cytokine IFN-␥.
Chromosome 16q13 Chemokine Expression as a Surrogate Marker of Th2-Type Immune Responses?
We have shown that the genes encoding the CC chemokines MDC and TARC are physically linked to the gene encoding the CX 3 C chemokine fractalkine on chromosome 16q13. The majority of the CC chemokine genes in the human genome have been mapped to a locus on chromosome 17q11.2. 25 The murine homologues of MDC, fractalkine, and TARC, ABCD-1, ABCD-2, and ABCD-3, respectively, are also physically linked in the murine genome. 26 It is striking that the expression of all 3 chemokine mRNAs in human macrophages is upregulated by treatment with the Th2-type cytokine IL-4 ( Figure 1B and 1C) . The very similar pattern of MDC, fractalkine, and TARC expression by macrophages within complex atherosclerotic plaques (Figure 4 and online Figure I ) suggests coordinate regulation of these linked chemokines in vivo, potentially by Th2-type cytokines. The measurement of chemokine mRNA levels in human arterial tissue samples revealed a wide range of levels of expression (Figure 3) , especially for the chemokine MDC, and it is possible that other cytokines and inflammatory stimuli might regulate chromosome 16q13 chemokine expression within the arterial wall.
Recent studies of the cytokine secretion profile of T lymphocytes recovered from human atherosclerotic plaques have suggested that the majority of CD4 ϩ T cells in unstable atherosclerotic plaques secrete IFN-␥ and, hence, are more likely to be associated with a Th1-type immune response. 27, 28 Mach et al 29 have reported that the CXC chemokines IP-10, Mig, and I-TAC are expressed in human atherosclerotic lesions. All 3 CXC chemokines are induced by IFN-␥; hence, their expression might be considered a surrogate marker of Th1 cytokine expression in human atherosclerotic lesions. The same group recently reported expression of the CC chemokine eotaxin and its receptor CCR3 in atherosclerotic lesions. 30 The eotaxin receptor CCR3 is preferentially expressed by Th2 T cells, and an increased number of CCR3-expressing T cells are seen in pathologies characterized by Th2-type immune responses, such as atopic dermatitis. 31 It is possible to envisage competing programs of Th1 and Th2 cytokine expression within the microenvironment of the developing atherosclerotic plaque. Th1-type cytokines would lead to macrophages expressing a more inflammatory program of gene expression, whereas a Th2-type immune response might give rise to a macrophage gene expression program more associated with neovascularization and fibrosis. 32 It is interesting that hypercholesterolemia leads to a switch from Th1-type to Th2-type immune responses in apoE-knockout mice. 33 
Role of MDC, Fractalkine, and TARC in Mononuclear Cell Recruitment and Retention Within Atherosclerotic Lesions
Soluble fractalkine can recruit monocytes, T lymphocytes, and NK cells via chemotaxis, 15 and immobilized forms of fractalkine have been shown to mediate tight adhesion independent of the expression of other endothelial cell surface receptors. 15, 16 The recent demonstration that immobilized recombinant fractalkine can mediate the tight adhesion of monocytes and T cells under flow conditions 17 makes the observed expression pattern of fractalkine in diseased human arteries especially interesting. Cells staining with the anti-COOH terminal fractalkine antiserum could be secreting soluble fractalkine, presenting secreted fractalkine immobilized on heparan sulfate or expressing full-length membraneassociated fractalkine. Soluble fractalkine shed within the atherosclerotic lesion might mediate chemotaxis of CX 3 CR1-expressing mononuclear cells. Macrophages expressing fulllength transmembrane forms of fractalkine within atherosclerotic lesions could serve to promote adhesion and retention of recruited monocytes and T cells within the developing lesion. Macrophage expression of MDC and TARC within the atherosclerotic lesion might act to preferentially recruit Th2-type T cells into larger atherosclerotic plaques, possibly via the developing microcirculation. Expression of MDC and TARC within lesions might lead to recruitment of Th2 T cells, which are associated with the elaboration of humoral immune responses. Th2-type immune responses within atherosclerotic lesions could give rise to autoantibodies against modified forms of LDL. 34 The heterogeneity in chemokine mRNA expression patterns seen in human atherosclerotic lesions suggests that the exact mechanisms of chemokine-mediated mononuclear cell recruitment in atherosclerosis may differ between individuals and perhaps even between different lesions within the same individual. The range of MDC mRNA levels seen in human atherosclerotic lesions suggests that human atherosclerotic lesions might display heterogeneity in their molecular pathology that might not be fully appreciated in animal models of atherosclerosis.
